Becker R C
Thrombosis Research Center, University of Massachusetts Medical School, Worcester.
Cardiology. 1991;79(3):188-210. doi: 10.1159/000174879.
In general terms, thrombotic disorders of the cardiovascular system are characterized by poorly regulated, nonphysiologic thrombus formation. Considered more specifically, however, pathologic thrombosis represents a critical imbalance, frequently at both the systemic and vascular levels, of coagulation, anticoagulation and fibrinolysis. Indeed, the balance is shifted toward coagulation, preventing normal physiologic blood flow. Anticoagulants have been a mainstay in the treatment of thrombotic disorders. However, emerging strategies have focused primarily on thrombus dissolution (fibrinolysis), which can be efficiently achieved with the administration of extrinsic plasminogen activators. Clearly, thrombolytic therapy is currently the most direct means of restoring blood flow, vital organ perfusion and hemostatic balance among patients with thrombotic disorders of the cardiovascular system.
一般而言,心血管系统的血栓形成紊乱的特征是血栓形成调控不佳且不符合生理状态。然而,更具体地说,病理性血栓形成代表了凝血、抗凝和纤溶在全身和血管水平上的严重失衡。实际上,平衡向凝血方向偏移,阻碍了正常的生理性血流。抗凝剂一直是血栓形成紊乱治疗的主要手段。然而,新兴策略主要集中在血栓溶解(纤溶)上,通过给予外源性纤溶酶原激活剂可以有效实现这一点。显然,溶栓治疗目前是恢复心血管系统血栓形成紊乱患者血流、重要器官灌注和止血平衡的最直接方法。